Join Growin Stock Community!

台新藥6838.TW Overview

TW StockBiotech. & Medical
(No presentation for 6838)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

台新藥（6838）Overall Performance

台新藥（6838）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

台新藥（6838） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

台新藥（6838）Key Information

台新藥（6838）Profile

Formosa Pharmaceuticals, Inc., a late-preclinical and early clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan. It is involved in developing APP13007, an aqueous-based ophthalmic nanosuspension that is in Phase III clinical trial for the treatment of post-operative pain and inflammatory eye conditions; TSY-0110, an antibody-drug conjugate; and TSY-0210, an antibiotic for drug resistant infections. The company also develops APP13002, a topical antibiotic for infectious eye diseases, such as blepharitis; and MPT0E028, a novel pan- histone deacetylase inhibitor for solid tumors, such as hepatomas and colorectal cancer, as well as lung fibrosis. It has a collaboration agreement with Eyenovia, Inc. for the development of novel ophthalmic therapeutic. The company was founded in 2010 and is headquartered in Taipei City, Taiwan.

台新藥（6838）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.49
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
339.46
PB Ratio
2.73
Price-to-FCF
30.30
METRIC
VALUE
vs. INDUSTRY
Gross Margin
4.52%
Net Margin
-610.38%
Revenue Growth (YoY)
-90.83%
Profit Growth (YoY)
-99.51%
3-Year Revenue Growth
39.44%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.49
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
339.46
PB Ratio
2.73
Price-to-FCF
30.30
Gross Margin
4.52%
Net Margin
-610.38%
Revenue Growth (YoY)
-90.83%
Profit Growth (YoY)
-99.51%
3-Year Revenue Growth
39.44%
3-Year Profit Growth
-%
default symbol

6838

台新藥

27.35D

-1.83%

(-0.02)

  • When is 6838's latest earnings report released?

    The most recent financial report for 台新藥 (6838) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6838's short-term business performance and financial health. For the latest updates on 6838's earnings releases, visit this page regularly.

  • What is the operating profit of 6838?

    According to the latest financial report, 台新藥 (6838) reported an Operating Profit of -44.61M with an Operating Margin of -4,896.93% this period, representing a growth of 14.05% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 6838's revenue growth?

    In the latest financial report, 台新藥 (6838) announced revenue of 911K, with a Year-Over-Year growth rate of -78.98%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 6838 have?

    At the end of the period, 台新藥 (6838) held Total Cash and Cash Equivalents of 291.83M, accounting for 0.14 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6838 go with three margins increasing?

    In the latest report, 台新藥 (6838) did not achieve the “three margins increasing” benchmark, with a gross margin of -570.69%%, operating margin of -4,896.93%%, and net margin of -6,495.17%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6838's profit trajectory and future growth potential.

  • Is 6838's EPS continuing to grow?

    According to the past four quarterly reports, 台新藥 (6838)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.39. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 6838?

    台新藥 (6838)'s Free Cash Flow (FCF) for the period is 24.92M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 103.82% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.